Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Philogen SpA's annualized net income for the quarter that ended in Dec. 2025 was €489.1 Mil. Philogen SpA's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €248.7 Mil. Therefore, Philogen SpA's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 196.70%.
The historical rank and industry rank for Philogen SpA's Return-on-Tangible-Equity or its related term are showing as below:
MIL:PHIL'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -24.28 Med: -5.99 Max: 108.54
Current: 108.54
During the past 6 years, Philogen SpA's highest Return-on-Tangible-Equity was 108.54%. The lowest was -24.28%. And the median was -5.99%.
MIL:PHIL's Return-on-Tangible-Equity is ranked better than 97% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs MIL:PHIL: 108.54
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Philogen SpA Return-on-Tangible-Equity Related Terms
Philogen SpA Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Philogen SpA's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:PHIL vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Philogen SpA's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Philogen SpA Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Philogen SpA's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Philogen SpA's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 196.70% mean?
Philogen SpA (MIL:PHIL) has a Return-on-Tangible-Equity of 196.70% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Philogen SpA and its competitors. According to the industry distribution chart, Philogen SpA ranks #36 out of 1199 companies in the Biotechnology industry, placing it in the top 3%.
Is Philogen SpA's Return-on-Tangible-Equity too high?
Philogen SpA's current Return-on-Tangible-Equity is 196.70%. Based on the distribution chart, Philogen SpA ranks #36 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Philogen SpA has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Philogen SpA ranks #36 out of 1199 companies for Return-on-Tangible-Equity. This places Philogen SpA in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Philogen SpA and its competitors. Philogen SpA's current Return-on-Tangible-Equity is 196.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Based on GuruFocus' analysis, Philogen SpA (MIL:PHIL) is currently considered Possible Value Trap. The stock's GF Value™ is €228.12, compared to a current price of €24.90 — trading 89.1% below its estimated fair value. The current Return-on-Tangible-Equity is 196.70%. Philogen SpA's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Philogen SpA (MIL:PHIL), the current Return-on-Tangible-Equity is 196.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Philogen SpA (MIL:PHIL) Overvalued in 2026?
Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued.
The current stock price of €24.90 is trading 89.1% below its estimated GF Value™ of €228.12.
GuruFocus considers Philogen SpA to be Possible Value Trap.
Key valuation signals for MIL:PHIL:
Return-on-Tangible-Equity: 196.70%
GF Value™: €228.12 vs. price of €24.90 (89.1% below fair value)
No single metric tells the full story. See the MIL:PHIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
62GF Score
Get the complete analysis for MIL:PHIL
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:PHIL has been successfully added to your 
